Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 24Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Fallopian Tube Neoplasms 7Carcinoma, Renal Cell 6Breast Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Colorectal Neoplasms 5Stomach Neoplasms 4Recurrence 4Melanoma 4Carcinoma, Non-Small-Cell Lung 4Vulvar Neoplasms 3Vaginal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Uterine Neoplasms 2Neoplasms 2Lymphoma 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1

Interventions

Bevacizumab 21-dodecylpyridoxal 2tremelimumab 1durvalumab 1Paclitaxel 1Injections 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Platinum-resistant Recurrent Ovarian Cancer × durvalumab × Gynecologic × Clear all
NCT03699449 2021-04-01

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Yonsei University

Phase 2 Unknown
104 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡